Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): A report from the Children's Cancer Group
Authors:
- John D. PotterJPJohn D. Potter
- Gregory H. ReamanGRGregory H. Reaman
- Thomas W. PendergrassTPThomas W. Pendergrass
- Leslie L. RobisonLRLeslie L. Robison
- 1 November 1996
- journal article
- research article
- Published by Springer Nature in Cancer Causes & Control
- Vol. 7 (6) , 581-590
Abstract
Nearly 80 percent of infant leukemias present with an abnormality involving the MLL gene at 11q23. Moreover, secondary acute myeloid leukemias (AML) that occur as the result of chemotherapy agents, which are known to inhibit DNA topoisomerase II, often manifest the same MLL abnormalities. It has been hypothesized that de novo infant leukemias may occur as a result of maternal exposure to agents in diet and medications that inhibit DNA topoisomerase II. Three epidemiologic studies of childhood leukemia with similar methodologies were conducted in the United States and Canada over the past 10 years by the Children's Cancer Group (CCG). Of the total 771 mothers of infants diagnosed at one year of age or less (a priori as containing DNA topoisomerase II inhibitors. There were no significant trends with increasing maternal consumption for either the overall group, or the acute lymphoblastic leukemia (ALL) stratum. However, within the AML stratum, there was a statistically significant positive association (P trend=0.04) with increasing consumption of DNA topoisomerase II-inhibitor containing foods (odds ratio [OR]=9.8, 95 percent confidence interval [CI]=1.1–84.8; OR=10.2, CI=1.1–96.4; for medium and high consumption, respectively). Other potential topoisomerase II inhibitors were explored; no significant findings were found. Results of this preliminary study, in combination with molecular data, should be used in future investigations of childhood leukemia (particularly, infant) to justify the incorporation of a detailed dietary history.Keywords
This publication has 24 references indexed in Scilit:
- Assessment of environmental and genetic factors in the etiology of childhood cancers: the Childrens Cancer Group epidemiology program.Environmental Health Perspectives, 1995
- Infant Leukemia, Topoisomerase II Inhibitors, and the MLL GeneJNCI: Journal of the National Cancer Institute, 1994
- Epipodophyllotoxins and secondary leukaemiaThe Lancet, 1993
- In utero rearrangements in the trithorax-related oncogene in infant leukaemiasNature, 1993
- THERAPY OF GENITAL HUMAN PAPILLOMAVIRUS INFECTIONS. PART II: METHODS OF TREATMENTInternational Journal of Dermatology, 1992
- Chromosomal changes in Chinese hamster AA8 cells caused by podophyllin, a common treatment for genital wartsMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1992
- Does bulk damage to DNA explain the cytostatic and cytotoxic effects of topoisomerase II inhibitors?Biochemical Pharmacology, 1991
- Rapid evaluation of topoisomerase inhibitors: Caffeine inhibition of topoisomerases in vivoTeratogenesis, Carcinogenesis, and Mutagenesis, 1990
- Secondary Acute Myeloid Leukemia in Children Treated for Acute Lymphoid LeukemiaNew England Journal of Medicine, 1989
- TOPOISOMERASES IN HUMAN DISEASEThe Lancet, 1988